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Abstract
Ventricular arrhythmias are responsible for the majority of sudden cardiac deaths (SCD), par-
ticularly in patients with structural heart disease. Coronary artery disease, essentially previous 
myocardial infarction, is the most common heart disease upon which sustained ventricular 
tachycardia (VT) occurs, being reentry the predominant mechanism. Other cardiac conditions, 
such as idiopathic dilated cardiomyopathy, Chagas disease, sarcoidosis, arrhythmogenic car-
diomyopathies, and repaired congenital heart disease may also present with VT in follow-up. 
Analysis of the 12-lead electrocardiogram (ECG) is essential for diagnosis. There are nume-
rous electrocardiographic criteria that suggest VT with good specificity. The ECG also guides 
us in locating the site of origin of the arrhythmia and the presence of underlying heart disease. 
The electrophysiological study provides valuable information to establish the mechanism of the 
arrhythmia and guide the ablation procedure, as well as to confirm the diagnosis when dubious 
ECG. Given the poor efficacy of antiarrhythmic drug therapy, adjunctive catheter ablation con-
tributes to reduce the frequency of VT episodes and the number of shocks in patients implanted 
with a cardioverter-defibrillator (ICD). ICD therapy has proven to be effective in patients with 
aborted SCD or sustained VT in the presence of structural heart disease. It is the only therapy 
that improves survival in this patient population and its implantation is unquestioned nowa-
days. (Cardiol J 2015; 22, 1: 12–24)
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Introduction
Cardiovascular disease remains the leading cau-
se of death. About half of all cardiovascular deaths 
occur suddenly [1, 2], mostly due to sustained ven-
tricular arrhythmias [3, 4]. Coronary artery disease 
(CAD), primarily a history of myocardial infarction 
(MI), represents the most common underlying 
heart disease upon which sustained monomorphic 
ventricular tachycardia (SMVT) and ventricular 
fibrillation (VF) develop. However, they can also 
occur in patients with other cardiac conditions, such 
as non-ischemic idiopathic dilated cardiomyopathy, 
Chagas disease, sarcoidosis, arrhythmogenic car-
diomyopathies or repaired congenital heart disease 
[5–7]. SMVT can also happen in the absence of 
structural heart disease (i.e. outflow tract ventri-
cular arrhythmias; idiopathic left ventricular [LV] 
tachycardia, but rarely has a fatal outcome.
This paper reviews the most relevant aspects 
of sustained VT associated to structural heart 
disease.
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Substrate and mechanisms of  
sustained ventricular tachycardia
VT occurring in the chronic phase of MI is usu-
ally topographically related to the infarcted region. 
Post-MI scarring represents the arrhythmogenic 
substrate for the development of a reentry cir-
cuit. Whereas the VT associated with a healed MI 
constitutes the clinical paradigm of reentry, focal 
activation by abnormal automaticity is the main 
mechanism involved in the VT arising from the 
ischemic border zone during acute ischemia [8–10].
In Chagas disease, areas of myocardial fibrosis, 
resulting from focal myocarditis processes, also 
constitute a predisposing substrate for generation 
of reentrant ventricular arrhythmias. These fibro-
tic zones are usually located in the epicardium or 
subepicardium, which has important implications 
for the ablation procedure [11, 12]. Unlike CAD, 
in Chagas disease SMVT can occur with minimal 
or no structural heart disease [13].
It is accepted that reentrant VT occurring in 
patients with previous MI originates mainly in bun-
dles of viable myocardium within the scar. In this 
setting, local heterogeneity of conduction times and 
duration of cellular refractory periods predispose 
to unidirectional block and enables the beginning 
of a reentrant circuit (Fig. 1).
Although focal VT has been described, scar-
-related reentry is the most common VT mecha-
nism in the majority of the cardiac conditions that 
lead to VT: non-ischemic dilated cardiomyopathy 
(small intramural scars); arrhythmogenic right 
ventricular cardiomyopathy (areas of fibrofatty 
replacement); sarcoidosis (intramyocardial granu-
lomas); surgically repaired congenital heart disease 
(ventriculotomy, patches) [7, 14, 15]. In non-
-ischemic dilated cardiomyopathy, bundle branch 
reentry can also occur, especially in patients with 
His-Purkinje disease (i.e. left bundle branch block 
[LBBB]; prolonged HV interval) [16].
Clinical presentation
Clinical presentation of patients with VT is va-
riable. If the arrhythmia is slow and stable, patients 
may experience palpitations, chest pain, dyspnea, 
or be completely asymptomatic. The clinical impact 
of the arrhythmia depends on several factors such 
as the VT cycle length, the LV systolic function, 
and the autonomic tone. In patients with Chagas 
disease SMVT can also occur in the absence of 
severe LV dysfunction and, hence, be hemody-
namically stable. Nonetheless, 2 retrospective 
analyses of the AVID Registry showed that the 
hemodynamic impact of the qualifying arrhyth-
mia was not a predictor of outcome [17, 18]. VT 
is often poorly tolerated leading to syncope and 
sudden cardiac death. Incessant VT (defined as 
recurrent episodes of VT that persist for hours), 
even if well tolerated, can lead to hemodynamic 
deterioration, heart failure, and death [14, 19]. It 
may become dramatic in patients with implantable 
cardioverter-defibrillator (ICD). This situation 
is named electrical storm when three or more 
episodes of sustained VT occur within 24 h, each 
requiring termination by an intervention (usually 
ICD shock) [7, 19, 20]. A recent meta-analysis con-
firmed that patients with electrical storm have an 
adverse prognosis, including higher mortality [21]. 
Moreover, repeated ICD shocks have been shown 
to contribute to LV impairment and additionally 
Figure 1. A. Simplified scheme of a reentrant circuit. When local block occurs during sinus rhythm (unidirectional 
block), the propagated impulse activates the zone of block (already repolarized) retrogradely and the reentry circuit 
initiates; B. Schematic circuit of ventricular tachycardia (and its components). Conduction pathways can be seen 
surrounded by areas of scar.
A B
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worsen patient’s prognosis, in terms of increased 
risk of hospitalization for heart failure and death 
[22–25]. Reduction in cardiac index and troponin 
I release have been attributed to ICD discharges 
[26–28]. Pathology studies showed that ICDs can 
cause direct myocardial injury, contraction band 
necrosis, fibrosis, myocardial cell damage and po-
ssibly persistent inflammation [29, 30].
Electrocardiographic manifestations
The first electrocardiographic (ECG) challenge 
we face is to make the diagnosis of VT. Although 
this arrhythmia may show some irregularity, 
SMVT in the presence of CAD is usually regular. 
Differential diagnosis should be made with other 
wide QRS complex regular tachycardias, such as 
supraventricular tachycardia (SVT) with bundle 
branch block (permanent or associated to rapid 
heart rate) and antidromic tachycardia (QRS fully 
preexcited).
Antidromic tachycardia occurs in patients with 
Wolff-Parkinson-White syndrome, usually young 
and without history of cardiovascular disease. The 
ECG shows high voltage QRS complexes in precor-
dial leads and not as wide as in VT. The diagnosis 
is easier after interruption of the tachycardia when 
a pattern of preexcitation during sinus rhythm (SR) 
(short PR interval, widened QRS with delta wave 
and repolarization disorders) can be seen.
The diagnosis of a wide QRS tachycardia is 
a real challenge for the physician, not only for the 
difficulty in recognizing certain ECG criteria, but 
also for the circumstances in which it occurs (often 
requiring a rapid diagnosis) and the consequences 
of an incorrect conclusion, which could be harmful 
for the patient. For example, a hemodynamically 
well-tolerated tachycardia can induce the physician 
to think of a supraventricular origin. If the tachy-
cardia is actually VT, verapamil administration in 
order to treat SVT can produce hypotension and 
transform a stable situation into a poorly tolerated 
VT requiring immediate electrical cardioversion. 
When evaluating a wide complex QRS tachycardia, 
it is important to remember that VT is the most 
common diagnosis (up to 80% of cases) [31].
Different ECG criteria for differentiating VT 
from SVT with aberrancy have been described 
[32–35]. The presence of any of them strongly 
suggests the diagnosis of VT (high specificity), but 
their absence does not rule it out (modest sensitivi-
ty). Table 1 summarizes the main proposed criteria.
P wave visualization allows us to establish 
the atrioventricular (AV) relationship. The lack of 
relationship between p waves and QRS complexes 
(AV dissociation) is virtually diagnostic of VT. 
Table 1. Electrocardiographic criteria for ventricular tachycardia.
VA relationship •	VA dissociation
•	Capture and fusion beats
•	VA relationship > 1
Precordial leads •	Absence of RS complexes (positive or negative concordance)
•	R to nadir S interval > 100 ms
Specific QRS patterns “Right BBB”-type morphology “Left BBB”-type morphology
Duration: •	> 140 ms •	> 160 ms
V1: •	Monophasic R wave •	r wave > 30 ms
•	R wave > R’ wave •	> 60 ms to nadir S
•	qR or RS complex •	Notched S wave
V6: •	R/S < 1 •	Q wave
•	QS or QR complex
aVR lead •	 Initial R wave
•	 Initial r or q wave > 40 ms
•	Notch on the descending limb of a negative  
onset and predominantly negative QRS
•	vi / vt < 1
If BBB in sinus rhythm •	Contralateral BBB during VT
•	Narrower QRS complex during VT
VA — ventriculo-atrial; BBB — bundle brunch block; vi — voltage of the initial 40 ms of the QRS complex; vt — voltage of the terminal 40 ms 
of the QRS complex; VT — ventricular tachycardia
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If more QRS complexes than p waves are observed, 
the diagnosis of VT is also very likely. The exi-
stence of capture (narrow QRS and equal to that 
during SR) or fusion beats (QRS of intermediate 
duration between those the during SR and during 
tachycardia) is synonymous to AV dissociation, and 
therefore, indicates VT (Fig. 2A). The absence of 
AV dissociation does not indicate SVT, i.e. VT with 
1:1 retrograde conduction or with underlying atrial 
fibrillation. In the latter case, a wide QRS, regular 
tachycardia is always VT.
The VT morphology in precordial leads gives 
us important information for diagnostic purposes. 
The absence of an RS complex from V1 to V6 
(positive or negative concordance) showed 100% 
specificity for the diagnosis of VT, except for very 
rare cases (i.e. patients with a history of previous 
extensive MI and QS complexes from V1 to V6 
during SR) it is unlikely for a conduction disorder 
to cause such an ECG pattern.
In the presence of RS complexes in precordial 
leads, an interval between the onset of the R wave and 
the deepest part of the S wave (namely, R to nadir S) 
> 100 ms also indicates VT (Fig. 2B). This criterion is 
based on the concept that ventricular beats originate 
in the diseased myocardium, far from the Purkinge 
fibers, with longer conduction times. Hence, the QRS 
complexes exhibit a slow upstroke and long duration.
Figure 2. A. Right bundle branch block-type ventricular tachycardia (VT) with dissociated p waves (arrows) and 
a capture beat (*); B. VT in a patient with Chagas cardiomyopathy. Some electrocardiographically criteria that indicate 
VT can be observed such as r nadir to S > 100 ms, pure R wave in V1, R/S ratio < 1 in V6, QRS duration 240 ms.
A
B
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According to QRS configuration in precordial 
leads (primarily in V1), VT morphology can be 
“classified” as “right bundle branch block (RBBB) 
like” or “LBBB like”. For each of these situations 
there are ECG patterns in V1 and V6 that suggest 
VT (Table 1). When these criteria are met in both 
V1 and V6 it is indicative of VT (Fig. 2B). Brugada 
et al. [33] developed a diagnostic algorithm using 
the aforementioned criteria, with good sensitivity 
(98.7%) and specificity (96.5%).
Recently, Vereckei et al. [34] focused attention 
on aVR lead and proposed a different algorithm 
using only this lead. The presence of an initial 
dominant R wave, an initial r or q wave lasting 
> 40 ms or a notch on the initial descendent wave 
of a predominantly negative QRS complex in aVR 
are indicative criteria of VT. The fourth criterion 
of the algorithm is a voltage ratio (vi/vt) measured 
in millivolts between the initial 40 ms (vi) and the 
terminal 40 ms (vt) of the QRS. A ratio < 1 would 
indicate a slower initial activation (less myocardial 
mass is activated in the same period of time) and 
indicates VT. Identification of an R wave in a VR 
lead as diagnostic of VT matches older concepts 
in that extreme right axis deviation (between –90° 
and –180°) is unlikely produced by a conducted beat 
and suggests a ventricular origin.
Another useful clue is to compare the QRS 
morphology during SR and during tachycardia. In 
the presence of bundle branch block during SR, 
a narrower QRS during tachycardia is suggestive of 
VT. Importantly, QRS duration should be measured 
in the lead that shows the widest QRS complex. 
Similarly, a QRS morphology with contralateral 
bundle branch block-like configuration than that 
during SR is more likely to be produced by VT. If no 
changes in the electrical axis or QRS morphology 
are seen, SVT may be assumed [36]. An exception 
to this rule is VT due to bundle-branch reentry, in 
which the QRS morphology during tachycardia and 
SR is often similar [37].
The ECG during SR also allows us to identify 
Q waves from remote MI. When the location of 
these Q waves matches that of negative QRS com-
plexes during tachycardia it also suggests VT [38].
By ECG analysis, more than 1 SMVT morp-
hology can be identified. In the latest consensus 
document on VT ablation the term multiple mo-
nomorphic VTs was established for more than 
1 morphologically distinct monomorphic VT, oc-
curring as different episodes [7]. On the other 
hand, pleomorphic VT was defined as more than 
1 morphologically distinct QRS complex sponta-
neously occurring during the same VT episode, 
but the QRS is not continuously changing (i.e. 2 or 
more “stable” morphologies) [7]. This phenome-
non (that differs from polymorphic VT) can be seen 
at the onset of a monomorphic VT, when a change 
in QRS configuration occurs towards a different but 
stable morphology. In contrast, polymorphic VT has 
a continuously changing QRS configuration from 
beat to beat [7]. By analyzing 1,881 SMVT episodes 
in patients with ICD (> 80% with coronary heart 
disease) we found an incidence of 6% of sponta-
neous pleomorphism and 19% of multiple morp-
hologies [39]. Both phenomena were associated to 
increased overall mortality, but only pleomorphism 
was an independent predictor of total mortality. The 
appearance of these morphological changes should 
be identified in patients’ follow-up in order to apply 
therapy changes towards prevention of progressive 
clinical worsening. In this setting, we reported 
the case of a patient with Chagas disease who had 
multiple VT morphologies (2 different VTs) and de-
veloped electrical storm with LV ejection fraction 
(LVEF) deterioration and decompensated heart 
failure. After radiofrequency catheter ablation of 
the 2 spontaneous VT, our patient remained free 
from VT episodes, with LVEF recovery [40].
Location of the origin  
of ventricular tachycardia
The ECG obtained during VT provides es-
sential information about the region of origin of 
the arrhythmia [41]. Importantly, surface ECG 
from a reentrant VT tends to locate the exit site 
of the circuit, rather than the circuit in which it is 
generated.
In general, the location must be defined on 
3 axes: (a) septal and lateral wall, (b) anterosuperior 
wall and inferior wall, (c) apical vs. basal region 
[35]. The bundle branch block pattern is related 
to ventricular activation sequence. VTs arising 
from LV lateral wall exhibit a RBBB-type pattern 
with wider QRS complexes due to sequential acti-
vation of both ventricles. VTs with septal origin 
can show LBBB-type pattern in V1 and narrower 
QRS complexes due to early involvement of the 
His-Purkinje fibers and simultaneous activation 
of the 2 ventricles. In the absence of CAD, most 
LBBB-VTs originate in the RV. In patients with 
previous MI, QRS polarity in inferior leads indica-
tes the activation sequence between the anterior 
and inferior wall. An inferior MI leaves a scar on 
the diaphragmatic wall that is the source of a VT 
with superior axis (negative QRS in aVF) in 80% 
of cases. Instead, VT originated in a previous 
anterior MI may have superior (55% of cases) or 
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inferior axis deviation (positive QRS in aVF, 45% 
of cases) [9]. Finally, the dominant polarity of the 
QRS complexes in precordial leads may be useful 
to differentiate VTs originating in basal regions of 
the LV from those arising from the apex. In apical 
VTs, ventricular activation spreads away from all 
precordial leads and surface ECG shows a pattern 
of negative concordance. The opposite situation 
happens in VTs originating in basal regions that 
are characterized by a positive concordance in the 
precordial leads.
Evaluation of patients with  
ventricular tachycardia
In patients with VT, the presence of underlying 
heart disease should be evaluated. Cardiac ultraso-
und provides excellent information in this regard. 
In addition to the assessment of ventricular systolic 
function, ventricular hypertrophy (indicative of 
hypertrophic cardiomyopathy) can be found, as well 
as regional wall motion abnormalities suggestive of 
previous MI (topographic correlation with coronary 
anatomy) or Chagas disease (usually anteroapical 
or posterobasal dyskinesia).
The 24-h ECG monitoring (Holter) does not 
provide additional information in patients with do-
cumented sustained VT. In patients with no history 
of VT, asymptomatic episodes of non-sustained 
VT (< 30 s duration) may be found. Nevertheless, 
Holter monitoring has not been useful in guiding 
antiarrhythmic drug (AAD) therapy [42].
In patients with ischemic cardiomyopathy and 
suspected VT (because of palpitations, presyncope 
or syncope), the aim of the electrophysiological 
study (EPS) is to induce sustained VT by pro-
grammed ventricular stimulation (class I recom-
mendation, level of evidence B) [14]. In the rest 
of cardiomyopathies above mentioned (other than 
ischemic cardiomyopathy) the EPS plays a minor 
role due to its low positive and negative predictive 
values (non-ischemic dilated cardiomyopathy) or 
lack of clinical evidence (Chagas disease) [14]. In 
the presence of a wide QRS tachycardia of difficult 
diagnosis, an EPS should be performed to dist-
inguish VT from SVT with aberrant conduction 
(class I recommendation, level of evidence C) 
[14]. In patients with SMVT candidates to cathe-
ter ablation, the EPS permits an identification of 
the tachycardia mechanism and helps to guide the 
ablation procedure (class I recommendation, level 
of evidence B) [14]. Although focal VTs can be 
initiated by burst pacing, the ability to reproducibly 
start and finish a VT by programmed ventricular 
stimulation is suggestive of reentry [8]. In the 
same way, a reentrant mechanism can be confirmed 
by entrainment maneuvers. Indeed, entrainment 
with manifest fusion in surface ECG can only oc-
cur in reentrant VT. Finally, the EPS can also be 
performed for risk stratification of sudden death in 
patients with previous MI, non-sustained VT and 
LVEF ≤ 40% (class IIa recommendation, level of 
evidence B) [14, 43, 44].
Therapy
The goals of therapy in patients presenting 
with VT are to decrease VT related symptoms and 
morbidity and to reduce the risk of death.
Treatment with AAD cannot be considered 
a sole therapy (see trails of ICD vs. AAD therapy 
below), except for special populations such as 
patients who did not meet criteria for ICD implan-
tation or those with mildly symptomatic VT and no 
structural heart disease.
However, AADs are usually prescribed as 
adjunctive therapy of ICD. Beta-blockers and 
sotalol confer clinical benefit in terms of reducing 
arrhythmia recurrences and ICD shocks [45, 46]. 
The OPTIC study compared 3 therapeutic schemes 
(beta-blockers; sotalol or amiodarone + beta-
-blockers) in patients implanted with an ICD [47]. 
The combination of amiodarone + beta-blockers 
was superior the other schemes in reducing ICD 
shocks but with an increased risk of drug-related 
adverse effects. Since 70% of patients assigned to 
the beta-blocker arm were free from ICD shocks, 
it is reasonable to keep patients with beta-blockers 
only and “wait” for the first shock to add amioda-
rone. Finally, dofetilide has also shown to decrease 
the frequency of VT/VF episodes in patients with 
ICD, even after failure of other AAD [48].
Implantable cardioverter-defibrillator
Early clinical studies that demonstrated be-
nefit with ICD therapy enrolled patients with LV 
dysfunction and aborted sudden cardiac death or 
poorly tolerated VT. Three randomized clinical 
trials (Table 2) compared the efficacy of ICD the-
rapy and AAD in this group of patients (secondary 
prevention) [49–51].
The first study was the AVID trial, which in-
cluded the largest number of patients (n = 1,016) 
resuscitated from VF; VT with syncope or poorly 
tolerated VT with LVEF < 40% [52]. This study 
was prematurely stopped because of a clear benefit 
of ICD therapy (significant 31% reduction of total 
mortality).
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The CIDS study enrolled 659 patients with 
similar characteristics, although it included 14% 
of patients with unexplained syncope and indu-
cible VT on EPS [49]. There was a non-significant 
reduction in total (19.7%) and arrhythmic (32.8%) 
death. A later report of 1 enrolling center of this 
study showed a significant reduction in mortality 
with extended follow-up [53].
The CASH study was the smallest one (n = 346) 
and included only patients with resuscitated sud-
den arrhythmic death [50]. Patients were younger 
(58 vs. 65 years old) and had higher LVEF (46% 
vs. 31–33%) than in the above-mentioned studies 
and up to 10% of patients had no structural heart 
disease. After excluding patients assigned to drug 
therapy with propafenone (who had increased mor-
tality), the analysis of the remaining 288 patients 
showed a non-significant 23.4% reduction in ove-
rall mortality with ICD compared to AAD therapy 
(amiodarone or metoprolol) [51].
Although the reduction in mortality was only 
significant in AVID, probably due to a greater sample 
size, it was consistent in the 3 studies. A meta-
-analysis that combined the databases from these 
3 studies showed a significant reduction in overall 
(RRR 28%, 95% CI 13–40%) and arrhythmic morta-
lity (RRR 50%, 95% CI 33–63%). Further subgroup 
analysis showed that the benefit was greatest in 
patients with low LVEF (< 30–35%) [54–56].
As shown in Table 2, inclusion criteria in these 
3 trials were similar but not the same. As opposed 
to the CASH study, in AVID and CIDS studies VT 
was differentiated from VF or cardiac arrest as 
entry criteria. Both studies reported subgroup 
analyses and showed no different ICD benefit in 
patients presented with VT or VF [49, 52]. The 
inclusion CASH study did not make any distinction 
in the qualifying rhythm.
The results of these studies were so over-
whelming that international guidelines recom-
mend ICD implantation in these patients as class I 
[57–60]. Nowadays, nobody questions the implan-
tation of an ICD in a patient with aborted cardiac 
arrest, documented VF or VT with hemodynamic 
compromise.
As stated above, stable VT is not considered 
a benign rhythm and poorly tolerated arrhythmia 
recurrences can occur [61, 62]. The adverse outco-
me of these patients is similar to that of patients 
with unstable VT [17, 18]. Moreover, benefit of 
ICD therapy appears to be not different in patients 
presenting with VT or VF. All these considerations 
make appropriate the indication of ICD therapy 
in patients with hemodynamically stable VT and 
LVEF ≤ 40% [60]. In patients with tolerated VT and 
LVEF > 40% recommendation of ICD implantation 
is more weak and catheter ablation may be helpful 
in preventing arrhythmia recurrences.
Table 2. Implantable cardioverter-defibrillator trials for secondary prevention of sudden death.
AVID CIDS CASH
Year of publication 1997 2000 2000
N 1016 659 288
Inclusion criteria •	Resuscitated from  
near-fatal VF
•	Sustained VT with  
syncope
•	VT with hemodynamic 
compromise and  
LVEF < 40%
•	Documented VF
•	Out-of-hospital  
cardiac arrest
•	Sustained VT  
with syncope
•	Symptomatic SVT  
and LVEF < 35%
•	Syncope and  
inducible SVT
•	Resuscitated from  
cardiac arrest secondary 
to sustained ventricular 
arrhythmias
Mean LVEF [%] 31 33 46
Follow-up [months] 18 36 57
Mortality control group [%] 36 10.2/year 45
Mortality ICD group [%] 25 8.3/year 36
Mortality relative reduction [%] 31 19.7 23
Mortality absolute reduction [%] 11 6 9
NNT 9 17 11
ICD — implantable cardioverter-defibrillator; LVEF — left ventricular ejection fraction; NNT — number of patients needed to be treated to save 
one life; SVT — supraventricular tachycardia; VF — ventricular fibrillation; VT — ventricular tachycardia
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Catheter ablation
Given the poor efficacy of drug therapy, per-
cutaneous ablation becomes the more attractive 
option to reduce the frequency of VT episodes and 
ICD shocks in these patients, including those with 
incessant VT [14].
The objectives of the ablation procedure are: 
(1) the non-induction of clinical VT (clinical VT 
refers to the spontaneous SMVT presented by the 
patient), (2) the non-induction of any SMVT, and 
(3) modification of the cycle length of induced VT 
(elimination of all VTs with cycle lengths equal to 
or greater than that of the clinical VT) [7].
As discussed previously, reentry is the predo-
minant mechanism in VT associated with structural 
heart disease. Inducible VT and a good hemody-
namic tolerance are 2 conditions that help for the 
ablation procedure, since catheter mapping should 
be performed during VT. This mapping allows the 
identification of the ventricular region from which 
the impulse arises (through sequences of activation 
and electrogram prematurity), scar areas (absence 
of electrograms), healthy myocardium (normal 
electrograms) and viable regions surrounding and 
within the scars (abnormal, diastolic and fractiona-
ted electrograms with multiple components, low 
voltages and prolonged duration). Areas with such 
abnormal electrograms are often related to the VT 
circuit, especially when recorded before the onset 
of the QRS during VT (Fig. 3).
By overdrive ventricular pacing techniques 
(resetting and entrainment of the tachycardia) 
the VT circuit can be defined, as well as its criti-
cal components (entrance and exit sites, shared 
isthmus of slow conduction, outer loops of the 
circuit, etc.) (Fig. 1B). Entrainment of VT can be 
performed by pacing at sites that are either within 
or outside the reentry circuit. Thus, analysis of the 
QRS configuration and intracardiac electrograms 
during entrainment, as well as the postpacing in-
terval after the last entrained beat can be used to 
identify the target sites for radiofrequency ablation 
(Table 3) [63]. The interval from the last stimulus 
that entrains the VT to the next local electrogram 
at the pacing site (postpacing interval — PPI) is 
equal (± 30 ms) to the tachycardia cycle length 
(TCL) when the pacing site is within the reentry 
circuit. When the interval from the last stimulus 
that entrains the tachycardia to the beginning of the 
last entrained QRS complex is equal (± 20 ms) to 
that from the local electrogram to the beginning of 
the QRS complex during VT it is also indicative that 
the pacing site is within the reentry circuit (Fig. 4). 
The configuration of the QRS complex during 
Figure 3. Surface electrocardiogram and intracardiac recordings showing abnormal electrograms at the site of origin 
of ventricular tachycardia (VT). A fractionated prepotential is recorded with the ablation catheter in the first 3 beats 
(VT). During radiofrequency delivery at that point VT is interrupted and ventricular pacing from the implantable 
cardioverter-defibrillator begins. This ventricular site that was recording a presystolic electrogram during VT, is now 
recording low-amplitude late potential at the end of the QRS. The abnormal potential recorded during VT identified 
a critical component of the reentry circuit; ABL — ablation catheter; RVA — right ventricular apex.
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entrainment also provides useful information. Sur-
face ECG fusion during entrainment occurs due to 
collision between the stimulated wavefront and the 
tachycardia. It can be seen when pacing outside the 
reentry circuit (PPI greater than TCL by > 30 ms) 
or at an outer loop of the circuit (PPI = TCL ± 30 ms). 
When the QRS morphology during entrainment is 
identical to that during VT, collision of both wave-
fronts occurs near the pacing site or in the zone of 
slow conduction of the circuit. It has been called 
entrainment with concealed fusion and together with 
a PPI = TCL identifies the central isthmus of the cir-
cuit, which is the main target for ablation (Fig. 4) [64]. 
Isolated mid-diastolic potentials are typically recor-
ded at these points. A stimulus that fails to capture 
the ventricles but interrupts the tachycardia is also 
indicative that the pacing site is at a protected zone 
that composes or is near the critical isthmus [65].
New technologies allow us to perform 3-dimen- 
sional (3D) electroanatomical geometry of the ven-
tricular chamber and visualize the position of the ab-
lation catheter in real time. Areas of scar, healthy and 
viable myocardium (voltage map) as well as regions 
near to and far from the site of origin of the tachycar-
dia (activation and propagation maps) can be identi-
fied and displayed by color-coding (Fig. 5) [66, 67]. 
This information, in conjunction with intracardiac 
recordings and entrainment techniques, is a valuable 
guide for VT ablation and contributes decisively to 
the success of the procedure.
Table 3. Different patterns of response to entrainment mapping.
PPI – TCL = 0 ± 30 ms   or   (S-QRS) – (EGM-QRS) = 0 ± 20 ms
NO                                  YES
Manifest fusion Remote bystander Outer loop
Concealed fusion Adjacent bystander               (S-QRS) × 100 / TCL
< 30% Exit site/distal isthmus
30–50% Central isthmus
50–70% Proximal isthmus
> 70% Inner loop
PPI — post-pacing interval; TCL — tachycardia cycle length; S-QRS — time from stimulus to QRS onset; EGM — time from local electrogram 
to QRS onset
Figure 4. Surface electrocardiogram and intracardiac recordings showing entrainment with concealed fusion of sustai-
ned monomorphic ventricular tachycardia. PPI – TCL = 30 ms and S-QRS – EGM-QRS = 4 ms. These findings suggest 
a critical isthmus site. See text for discussion; ABL — ablation catheter; CS — coronary sinus; RA — right atrium; 
PPI — post-pacing interval; TCL — tachycardia cycle length; S-QRS — time from stimulus to QRS onset; EGM — time 
from local electrogram to QRS onset.
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In general, the ablation is effective acutely, and 
produces the abolition of 1 or more scar-related 
SMVT in up to 77–95% of cases [68, 69]. How-
ever, VT recurrence with the same morphology, 
or more often with a different morphology, may 
occur in 12–50% of patients, and further ablation 
procedures may be needed. In consequence, suc-
cessful VT ablation does not eliminate the need for 
ICD therapy or AAD. Epicardial ablation, through 
percutaneous access of the pericardial space guided 
by fluoroscopy and contrast injection, may also be 
needed, especially in Chagas disease [69, 70].
In cases of unmappable (non-inducible, poorly 
tolerated, or morphology-changing) VT, substrate 
ablation during SR can be performed by the use of 
3D navigation systems. With this technique, radio-
frequency energy is delivered in regions with scar 
tissue that topographically correlate to the region 
of origin of VT, as suggested by the ECG, where 
abnormal (fractionated, late, low voltage) potentials 
are recorded [7]. Areas of extremely low voltage 
(< 0.5 mV) are designated as “dense scar”, but it 
is important to recognize that these regions can 
still contain viable myocytes and reentry circuit 
isthmuses [71]. Linear radiofrequency lesions ex-
tended from the dense scar to anatomic boundaries 
or normal endocardium are effective in controlling 
unmappable VT [72, 73]. Local stimulation at that 
point during SR (“pacemapping technique”) can 
reproduce the VT morphology if the catheter is 
located near the exit site of the reentrant circuit. 
This technique is often combined with substrate 
mapping to define the potential exit, which can 
be identified along the border of the scar [72, 
74]. Radiofrequency lesions can then be placed 
parallel to the infarct border zone (where bipolar 
electrogram amplitude is typically between 0.5 mV 
and 1.0 mV). Sites where pacing produces a long 
S-QRS but matches the VT morphology are seen 
at some reentry circuit isthmus sites and can also 
be targeted for ablation [75]. However, pacemap-
ping is more useful in cases of focal VT, and can 
be confusing in reentrant VT. Abnormal potentials 
recorded during sinus or paced rhythm allow the 
identification of potential channels within the dense 
scar and have been targeted for ablation with good 
results [76–78].
Substrate ablation was evaluated in patients 
with previous MI and ICD implantation for second-
ary prevention of SCD in the SMASH-VT study 
[79]. Patients (n = 128) were randomized to ICD 
alone or ICD + substrate ablation. The ablation 
group showed a significant 65% reduction in ICD 
therapies for VT/VF and a non-significant 47% im-
provement in survival, without procedure-related 
mortality. More recently, local abnormal ventricular 
activities (so-called LAVAs) have been identified 
as a new target for substrate ablation in patients 
with scar-related VT [80]. LAVAs were defined as 
high-frequency ventricular potentials occurring 
during or after the far-field ventricular electrogram 
(not necessary late potentials) and their abolition 
was associated with lower VT recurrence. Another 
end-point described for substrate modification is 
the endo-epicardial homogenization of the scar 
(ablation of all abnormal potentials recorded within 
Figure 5. Electroanatomic voltage 3-dimensional maps from EnSite Navx (St. Jude Medical). A. Large scar (grey zone) 
in the apical anterolateral region of the left ventricle in a patient with previous myocardial infarction. Viable zones 
surrounding and within the dense scar (red-yellow) and healthy zones (purple) can be observed, as well as, radiofre-
quency lesions (brown dots); B. Basal posterloateral scar in a patient with Chagas cardiomyopathy.
A B
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the scar). In patients with ischemic cardiomyopathy 
and electrical storm, this technique was superior to 
limited substrate ablation in terms of freedom from 
arrhythmia [81]. In non-inducible patients without 
ECG documentation of clinical VT, elimination of 
all areas with late potentials has also proved to 
reduce arrhythmia recurrence [82].
For patients with non-tolerated VT, hemodyna-
mic support systems (so-called LV assist devices) 
are increasingly used. These percutaneous devices 
are retrogradely placed via aorta and basically ex-
tract blood from LV and deliver it in the proximal 
aorta. It results in a better hemodynamic tolerance 
of the arrhythmia and allows mapping [83]. Both 
Impella and TandemHeart devices gave a good 
hemodynamic support and were superior to intra-
-aortic balloon pump [84, 85].
An understanding of anatomy is important 
for mapping and ablation. Pre-procedural imaging 
(magnetic resonance imaging [MRI], computed 
tomography [CT] or positron emission tomograp-
hy [PET]-CT) is usually obtained to identify the 
arrhythmia substrate and anatomic obstacles to 
ablation. Magnetic resonance is perhaps the more 
accurate imaging method to define scar extension 
and tachycardia-related conducting channels [86, 
87]. Unfortunately, MRI is limited in these pa-
tients since many of them have implanted devices. 
Contrast-enhanced CT and PET can be performed 
in patients with cardiac devices and have also been 
used to guide VT ablations [88, 89]. The images 
obtained by these methods can be incorporated 
into the 3D navigator systems to help the anatomic 
reconstruction.
In the case of bundle-branch reentry VT, abla-
tion of the RBBB is the treatment of choice [90]. 
However, given that it usually occurs in patients 
with dilated cardiomyopathy, the occurrence of 
myocardial VT in follow-up usually requires addi-
tional interventions such as ICD implantation or 
further ablation.
Conclusions
Evaluation of patients with VT should begin 
with a thorough analysis of the ECG. The EPS is 
essential to establish the arrhythmia mechanism 
and to guide the ablation procedure. ICD therapy 
improves survival in secondary prevention of 
sudden death. Catheter ablation of VT reduces the 
number of VT episodes and ICD shocks.
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